Evaxion A (EVAX) EBITDA Margin (2024 - 2025)
Evaxion A (EVAX) posted EBITDA Margin of 40.34% for Q3 2025, up 343981.4% on a QoQ basis from 0.01% in Q2 2025, and up 9771.0% year-over-year from 0.41% in Q3 2024.
Evaxion A (EVAX) EBITDA Margin (2024 - 2025) Analysis & Trends
Evaxion A's EBITDA Margin history runs 2 years deep, the most recent figure standing at 40.34% for Q3 2025.
- Quarterly EBITDA Margin rose 9771.0% year-over-year to 40.34% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 0.02% (up 43131.0% YoY) and the FY2025 annual result came in at 122.66%, up 31789.0% from the prior year.
- EBITDA Margin was 40.34% for Q3 2025 at Evaxion A, up from 0.01% in the prior quarter.
- Across five years, EBITDA Margin topped out at 40.34% in Q3 2025 and bottomed at 8619.61% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Evaxion A | 1.23 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 40.34% |
| Jun 30, 2025 | -0.01% |
| Dec 31, 2024 | -3,298.36% |
| Sep 30, 2024 | -57.37% |
| Jun 30, 2024 | -2,974.68% |
| Mar 31, 2024 | -8,619.61% |